Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice by White, HA et al.
1 
 
Latent tuberculosis infection screening and treatment in HIV: insights from 
evaluation of UK practice 
 
Helena A White1,2 
Robert F Miller3 
Anton L Pozniak4 
Marc C I Lipman5 
Iain Stephenson1 
Martin J Wiselka1,2 
Manish Pareek1,2 
 
1 Department of Infection and Tropical Medicine, Leicester Royal Infirmary, Leicester, United Kingdom 
2 Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United 
Kingdom 
3 Research Department of Infection and Population Health, University College London, United Kingdom. 
4 HIV Department, Chelsea and Westminster Hospital, London, United Kingdom 
5 UCL Respiratory, Division of Medicine, University College London, United Kingdom 
 
Corresponding author: Dr. Manish Pareek  
Department of Infection, Immunity and Inflammation, University of Leicester, United Kingdom.  
Email: mp426@le.ac.uk 
 
Keywords: Latent tuberculosis, Chemoprophylaxis, Human Immunodeficiency Virus, Screening 
Evaluation of practice 
Number of pages (including title page and references): 11 
Abstract word count: 100 
Manuscript word count: 1204 
Number of tables:  2 
 
2 
 
Abstract 
 
Latent tuberculosis infection (LTBI) screening and treatment in HIV positive individuals in the 
UK is advocated by the British HIV Association (BHIVA) and NICE, although each 
recommends differing strategies. We undertook an evaluation of UK practice, relating the 
responses to the local HIV/TB disease burden. 162 of 188 (86%) UK geographical areas 
responded; only 93/162 (57.4%) offer LTBI testing with considerable heterogeneity in practice, 
and no difference in HIV/TB burden between areas offering testing and those who do not. Only 
33/93 (35.5%) and 6/93 (6.5%) reported full compliance with BHIVA and NICE guidance 
respectively. A uniform national guideline is required. 
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INTRODUCTION 
 
HIV positive individuals are at an increased risk of acquiring tuberculosis (TB) and progressing 
to active disease through reactivation of latent TB infection (LTBI) (1). Analysis of the incident 
TB rate in the UK HIV positive cohort, demonstrates that there are high rates in Black Africans, 
those with a low blood CD4 count, and that rates are also higher in white individuals, than in the 
background HIV negative white population. This is despite access to, and widespread use of, 
anti-retroviral therapy (ARV) (2).  
 
An increasing drive by the World Health Organization to identify and treat LTBI in HIV positive 
individuals as part of TB control (3,4), particularly in high HIV prevalence/low income settings, 
is supported by a Cochrane meta-analysis that found treating LTBI in this group reduced the risk 
of active TB by 32% (5). Since mortality from HIV/TB remains high in the UK (6), there are 
calls for expanded LTBI screening and treatment here (2). 
 
Currently, LTBI screening in HIV positive individuals is advocated by the British HIV 
Association (BHIVA) (7) and the National Institute of Health and Care Excellence (NICE). The 
NICE guidance in place at the time of this evaluation was from 2011 (8). BHIVA recommend 
screening selected individuals with an interferon gamma release assay (IGRA), dependent upon 
a combination of criteria including the region of origin, duration of receipt of ARV and the CD4 
count. NICE advocate screening all those with a CD4 count of 200 - 500 cells/ mm3 with an 
IGRA plus the additional option of a tuberculin skin test (TST), with a definite recommendation 
of IGRA plus TST in those with CD4 <200 cells/mm3. Chemoprophylaxis is advocated by both 
if LTBI is diagnosed. Little is known about whether, and how, HIV healthcare providers 
implement these guidelines. A national evaluation of UK practice is therefore highly topical and 
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policy relevant with respect to understanding how screening is provided, the level of adherence 
to current guidance and whether the HIV/TB burden in different centres has any impact on 
practice. 
 
METHODS  
 
Questionnaire design 
An online questionnaire was devised and one HIV professional working for each HIV healthcare 
provider organisation in the UK was invited to participate in the evaluation.  
 
HIV prevalence and TB incidence data 
188 geographical areas in the UK were identified and had data available on HIV prevalence and 
TB incidence data. 
 
Full details of the methods are available in the supplementary information. 
 
RESULTS 
 
Response rate 
Responses were obtained from 116 individuals, representing 162 UK geographical areas, since 
some respondents provided HIV care for more than one geographical area. The overall response 
rate was therefore considered to be 162/188 (86%). 
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HIV and TB burden in all geographical areas 
There was no difference in HIV/TB burden between those geographical areas who did, and did 
not, respond to the survey (p =1.000). 
 
Size of HIV cohort in responding areas 
The total number of patients reported as being treated within their HIV centres by the 116 
respondents was 73,395 (90% of total HIV cohort reported by PHE in 2014 (9)). The median 
was 300, range 10-8,000 and inter-quartile range 170-700. 
 
Coverage of screening HIV positive patients for LTBI 
Only 93/162 (57.4%) of geographical areas reported offering any form of LTBI screening, with 
no difference in HIV/TB burden between the geographical areas who offered screening and 
those who did not (p=0.22) (Table 1).  
 
 
Table 1. HIV/TB categories by LTBI screening 
 
 
 
HIV prevalence and TB incidence             
rate category                                                   
 
Offer screening 
n (%) 
Do not offer screening 
n (%) 
High HIV/High TB1                                  
 
17 (18.3) 17 (24.6) 
High HIV/Low TB2                                      
 
8 (8.6) 3 (4.3) 
Low HIV/High TB3                                     
 
2 (2.2) 5 (7.2) 
Low HIV/Low TB4                                     
 
66 (71) 44 (63.8) 
Total                                                          
 
93 (100) 69 (100) 
Footnotes 
1High HIV: >2/1,000 HIV prevalence; High TB: >20/100,000 TB incidence 
2High HIV: >2/1,000 HIV prevalence; Low TB: ≤20/100,000 TB incidence   
3Low HIV: ≤2/1,000 HIV prevalence; High TB: >20/100,000 TB incidence 
4Low HIV: ≤2/1,000 HIV prevalence; Low TB: ≤20/100,000 TB incidence 
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Selection of patients to screen for LTBI  
Of the geographical areas offering any kind of LTBI screening, 57/93 (61.3%) reported using the 
current CD4 count as a screening criterion, with 53/57 (93%) screening adults with a CD4 count 
of ≤ 200 cells/mm3 but decreasing numbers offering screening at higher CD4 counts (Table 2). 
75/93 (80.6%) used the patient’s country of origin, with all screening those from high TB 
incidence countries, but fewer than two thirds screening from any other region. The duration of 
receipt of ARV treatment was the least utilised criterion. 
 
Table 2. Criteria used to guide LTBI screening  
 
 
Screening criteria  
n (%) 
Total  n = 93 geographical areas 
offering screening 
 
CD4 count criteria  
CD4 count ≤50 
CD4 count ≤100 
CD4 count ≤200 
CD4 count ≤350 
CD4 count ≤500 
CD4 count >500 
Other reported CD4 count criteria - Individual assessment 
 
Country of origin criteria  
High TB incidence country >40/100,000 pop. 
Medium TB incidence country 20-40/100,000 pop. 
Low incidence TB country <20/100,000 pop. 
Other reported criteria – Eastern European countries 
 
Duration receiving ARV criteria  
Under 6 months 
Under 1 year 
Under 2 years 
Other reported criteria – Individual assessment 
 
57             (61.3) 
53/571        (93) 
53/571      (93) 
53/571        (93) 
51/57        (89.5) 
45/57        (79) 
33/57        (57.9) 
4/57          (7) 
 
75             (80.6) 
75/75        (100) 
49/75        (65.3) 
35/75        (46.7) 
1/75          (1.3) 
 
52             (60) 
48/52        (92.3) 
42/52        (80.8) 
42/52        (80.8) 
4/52          (7.7) 
 
Footnote 
153 centres offering screening to patients with a CD4 count of ≤ 200 are the same centres offering screening to those 
with CD4 counts in the ≤ 100 and ≤ 50 categories 
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LTBI screening tests 
IGRA tests were implemented most commonly; 44/93 (47.3%) and 42/93 (45.2%) of 
geographical areas reported using QuantiFERON and T.SPOT tests respectively.  Other 
screening methods or combinations of tests were utilised infrequently.  
 
Adherence to national guidance 
Only 33/93 (35.5%) and 6/93 (6.5%) reported complete adherence to BHIVA and NICE 
guidelines, respectively. No geographical area reported using any non-UK guidelines. 
 
Multifactorial reasons for not screening 
Of the geographical areas not offering screening, 31/69 (45%) believed their cohort was at low 
risk of latent TB infection.  20/69 (29%) cited a lack of confidence in the existing guidelines. 
12/69 (17.4%) reported that the tests were too expensive, with 10/69 (14.5%) and 8/69 (11.6%) 
reporting unavailability of T.SPOT TB and QuantiFERON Gold In-Tube test (or other version) 
respectively.  A few areas cited reasons such as wanting a cost-effectiveness analysis, concern 
over chemoprophylaxis efficacy, toxicity/drug-drug interactions, and conflicting local advice. 
 
Management of LTBI  
Eighty eight of the 93 (94.6%) geographical areas undertaking LTBI screening offer 
chemoprophylaxis. The most common regimens reported were six months isoniazid (62/88, 
70.5%), three months combined isoniazid/rifampicin (49/88, 55.7%), nine months isoniazid 
(5/88, 5.7%), and combined rifampicin/isoniazid/ethambutol (1/88, 1.1%). 
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Future intention to offer LTBI screening and treatment  
Of the 69 geographical areas not currently offering LTBI screening, 22 (31.9%) indicated a 
future intention to do so. 
 
Full details of the results are available in the supplementary information. 
 
DISCUSSION 
 
This national evaluation, covering over 90% of HIV positive adults in the UK, is the first to 
evaluate LTBI screening in this population. It reveals that screening practices are highly 
heterogeneous in terms of the screening criteria and the tests utilised, and often deviate from 
published national guidance, although these are themselves non-congruent. Additionally, 
screening policy was not dependent on the local burden of HIV/TB. 
 
Most cases of active tuberculosis in the UK occur through the reactivation of LTBI in foreign-
born individuals. Identification, and treatment of LTBI in high-risk populations (such as those 
with HIV infection) in the context of a low-burden TB setting such as the UK, where there is 
relatively little ongoing exposure to Mycobacterium tuberculosis, has the potential to augment 
TB control and prevent morbidity and mortality. However, our work indicates that despite two 
national guidelines, a relatively low proportion (57.4%) of areas in the UK currently perform any 
kind of systematic LTBI screening, although a further 14% have expressed a future intention to 
do so.  
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Interestingly, the most commonly reported explanation for not offering LTBI screening was a 
perception that the cohort was at low risk of TB infection, although a quarter of geographical 
areas not offering screening, have high HIV prevalence/TB incidence.  
 
A lack of confidence in the published guidance, and a view that the current guidelines are too 
complex were also cited. Although not explicitly stated by the respondents, having two different 
published guidelines on the same topic may well cause confusion and uncertainty amongst 
clinicians. Unavailability or high cost of screening tests was the next most reported explanation, 
raising questions about equitable resource allocation. 
 
Although observational, epidemiological cohort data supports antiretroviral use with wider LTBI 
screening in HIV positive individuals to prevent active TB, there is an urgent need to 
prospectively asses which individuals to offer screening to, the optimal screening strategy and 
the cost-effectiveness of screening in an era of widespread antiretroviral therapy use, thereby 
informing future national guidance. 
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